SUNPHARMA's weekly performance was disappointing, with a return of -2.85% and a Sharpe Ratio of -0.67, indicating poor risk-adjusted returns. The stock's volatility was relatively high at 17.0%, making it a risky investment this week. Compared to its peers, SUNPHARMA underperformed DRREDDY but outperformed DIVISLAB and HINDUNILVR in terms of returns. Overall, the stock's performance was lackluster and risky.

[Volatility: 17.0%]